Annovis Bio Inc. Expands Patent Portfolio for Buntanetap, Enhancing Treatment Options for Neurodegenerative Diseases

Annovis Bio Inc. (NYSE: ANVS), a leader in the development of treatments for neurodegenerative diseases, has announced a significant milestone in its intellectual property strategy. The company has successfully expanded its patent portfolio to fully cover both the original and a new crystalline form of buntanetap, a promising therapeutic agent. This comprehensive protection, extending through 2046, encompasses the composition of matter, mechanism of action, and use in multiple indications, solidifying Annovis Bio's position in the neurodegenerative disease treatment landscape.

The new crystalline form of buntanetap has demonstrated improved stability, with bioequivalence confirmed in both animal and human studies. These findings were recently presented at the 2025 Alzheimer’s Association International Conference, highlighting the potential of buntanetap to offer more reliable and effective treatment options for patients suffering from Alzheimer’s disease (AD) and Parkinson’s disease (PD). The ability to maintain bioequivalence while improving the drug's stability is a critical advancement, as it ensures that the therapeutic benefits of buntanetap can be consistently delivered to patients.

This development is particularly significant given the growing global burden of neurodegenerative diseases. With an aging population, the prevalence of conditions like AD and PD is expected to rise, underscoring the need for innovative treatments that can halt or reverse disease progression. Annovis Bio's expanded patent portfolio not only enhances the company's competitive edge but also contributes to the broader effort to address unmet medical needs in neurodegeneration.

For more details on Annovis Bio's groundbreaking work and its implications for the future of neurodegenerative disease treatment, visit https://ibn.fm/gtiNb. Additionally, investors and stakeholders can stay updated on the latest developments from Annovis Bio by visiting the company's newsroom at https://ibn.fm/ANVS.

The expansion of Annovis Bio's patent portfolio for buntanetap represents a pivotal step forward in the fight against neurodegenerative diseases. By securing comprehensive intellectual property protection and demonstrating the improved stability of its lead compound, the company is well-positioned to advance its clinical programs and bring much-needed therapies to patients worldwide.